Highlights from Ayrton Drug's Annual Report- Chairman's Letter

• The Chairman said 2012 was a tough year for the company. Top-line (Sales) grew by 14.68% but the bottom-line ( Profit after tax) fell by 13.61%. This he attributed to the depreciating cedi and astronomical increases in interest rates, among other factors.

• Earnings per share fell from 0.0133p in 2011 to 0.0115 in 2012 whiles dividend per share remained at 0.125p

• Plans are far advanced to build a new facility in a bid to improve the bottom line. There would also be restructuring of the company to increase efficiency of all the Departments.